<i>In vivo</i> efficacy of sEphB4-HSA combined with Bevacizumab. Xiuqing Li Wesley W. Choi Rui Yan Haiyang Yu Valery Krasnoperov S. Ram Kumar Anne Schuckman David J. Klumpp Chong-Xian Pan David Quinn Inderbir S. Gill Parkash S. Gill Ren Liu 10.1371/journal.pone.0105326.g003 https://plos.figshare.com/articles/figure/_In_vivo_efficacy_of_sEphB4_HSA_combined_with_Bevacizumab_/1149461 <p>A, 5637 tumors were treated with sEphB4-HSA alone (20 mg/kg, 3 times a week), Bevacizamab alone (20 mg/kg, 3 times a week), or sEphB4-HSA combined with Bevacizamab. PBS was used as control. Data are presented as mean ± standard deviation. Student <i>t</i>-test (2 tails, unpaired) was used to calculate P value: *, P<0.05; **, P<0.01. B, tumors harvested from the xenograft study were lysed for EphB4 immunoprecipitation, followed by immunoblotting using EphB4 and phopho-tyrosine antibodies. sEphB4-HSA treatment significantly reduced EphB4 tyrosine phosphorylation <i>in vivo</i>.</p> 2014-08-22 03:36:13 Transitional Cell Carcinoma EphB 4 expression bladder tumor xenograft survival factor tumor cell lines 24 cases EphB 4 signal strength EphB 2 EphB 4 EphB 4 Receptor Kinases cis tyrosine kinase activity TCC specimens show loss